The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Pharmacotherapies for sleep disturbances in dementia
Open accessAbstract
BACKGROUND: Sleep disturbances, including reduced nocturnal sleep time, sleep fragmentation, nocturnal wandering, and daytime sleepiness are common clinical problems in dementia, and are associated with significant caregiver distress, increased healthcare costs, and institutionalisation. Drug treatment is often sought to alleviate these problems, but there is significant uncertainty about the efficacy and adverse effects of the various hypnotic drugs in this vulnerable population. OBJECTIVES: To assess the effects, including common adverse effects, of any drug treatment versus placebo for sleep disorders in people with dementia, through identification and analysis of all relevant randomised controlled trials (RCTs). SEARCH METHODS: We searched ALOIS (www.medicine.ox.ac.uk/alois), the Cochrane Dementia and Cognitive Improvement Group's Specialized Register, in March 2013 and again in March 2016, using the terms: sleep, insomnia, circadian, hypersomnia, parasomnia, somnolence, rest-activity, sundowning. SELECTION CRITERIA: We included RCTs that compared a drug with placebo, and that had the primary aim of improving sleep in people with dementia who had an identified sleep disturbance at baseline. Trials could also include non-pharmacological interventions, as long as both drug and placebo groups had the same exposure to them. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data on study design, risk of bias, and results from the included study reports. We obtained additional information from study authors where necessary. We used the mean difference as the measure of treatment effect, and where possible, synthesized results using a fixed-effect model. MAIN RESULTS: We found six RCTs eligible for inclusion for three drugs: melatonin (222 participants, four studies, but only two yielded data on our primary sleep outcomes suitable for meta-analysis), trazodone (30 participants, one study), and ramelteon (74 participants, one study, no peer-reviewed publication, limited information available).The participants in the trazodone study and almost all participants in the melatonin studies had moderate-to-severe dementia due to Alzheimer's disease (AD); those in the ramelteon study had mild-to-moderate AD. Participants had a variety of common sleep problems at baseline. All primary sleep outcomes were measured using actigraphy. In one study of melatonin, drug treatment was combined with morning bright light therapy. Only two studies made a systematic assessment of adverse effects. Overall, the evidence was at low risk of bias, although there were areas of incomplete reporting, some problems with participant attrition, related largely to poor tolerance of actigraphy and technical difficulties, and a high risk of selective reporting in one trial that contributed very few participants. The risk of bias in the ramelteon study was unclear due to incomplete reporting.We found no evidence that melatonin, at doses up to 10 mg, improved any major sleep outcome over 8 to 10 weeks in patients with AD who were identified as having a sleep disturbance. We were able to synthesize data for two of our primary sleep outcomes: total nocturnal sleep time (mean difference (MD) 10.68 minutes, 95% CI -16.22 to 37.59; N = 184; two studies), and the ratio of daytime sleep to night-time sleep (MD -0.13, 95% CI -0.29 to 0.03; N = 184; two studies). From single studies, we found no difference between melatonin and placebo groups for sleep efficiency, time awake after sleep onset, or number of night-time awakenings. From two studies, we found no effect of melatonin on cognition or performance of activities of daily living (ADL). No serious adverse effects of melatonin were reported in the included studies. We considered this evidence to be of low quality.There was low-quality evidence that trazodone 50 mg given at night for two weeks improved total nocturnal sleep time (MD 42.46 minutes, 95% CI 0.9 to 84.0; N = 30; one study), and sleep efficiency (MD 8.53%, 95% CI 1.9 to 15.1; N = 30; one study) in patients with moderate-to-severe AD, but it did not affect the amount of time spent awake after sleep onset (MD -20.41, 95% CI -60.4 to 19.6; N = 30; one study), or the number of nocturnal awakenings (MD -3.71, 95% CI -8.2 to 0.8; N = 30; one study). No effect was seen on daytime sleep, cognition, or ADL. No serious adverse effects of trazodone were reported.Results from a phase 2 trial investigating ramelteon 8 mg administered at night were available in summary form in a sponsor's synopsis. Because the data were from a single, small study and reporting was incomplete, we considered this evidence to be of low quality in general terms. Ramelteon had no effect on total nocturnal sleep time at one week (primary outcome) or eight weeks (end of treatment) in patients with mild-to-moderate AD. The synopsis reported few significant differences from placebo for any sleep, behavioural, or cognitive outcomes; none were likely to be of c
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671
Lyketsos, C. G., Steinberg, M., Tschanz, J. T., Norton, M. C., Steffens, D. C., & Breitner, J. C. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.708 · Cited by 1,144
Schneider, L. S., Dagerman, K., & Insel, P. S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000200589.01396.6d · Cited by 903
Riemersma-van der Lek, R. F. (2008) · JAMA · doi:10.1001/jama.299.22.2642 · Cited by 803
Guarnieri, B., Adorni, F., Musicco, M., Appollonio, I., Bonanni, E., Caffarra, P., Caltagirone, C., Cerroni, G., Concari, L., Cosentino, F. I. I., et al. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000335363 · Cited by 393
Afram, B., Stephan, A., Verbeek, H., Bleijlevens, M. H. C., Suhonen, R., Sutcliffe, C., Raamat, K., Cabrera, E., Soto, M. E., Hallberg, I. R., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.09.012 · Cited by 230
Camargos, E. F., Louzada, L. L., Quintas, J. L., Naves, J. O. S., Louzada, F. M., & Nóbrega, O. T. (2014) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.12.174 · Cited by 170
Oderda, L. H., Young, J. R., Asche, C. V., & Pepper, G. A. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q589 · Cited by 94
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation
Zisapel, N. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14116 · Cited by 860
(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-804766-8.00013-3 · Cited by 783
Melatonin as a Hormone: New Physiological and Clinical Insights
Cipolla-Neto, J., & Amaral, F. G. D. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00084 · Cited by 635
Circadian disruption and human health
Fishbein, A. B., Knutson, K. L., & Zee, P. C. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148286 · Cited by 468
Circadian rhythms and disorders of the timing of sleep
Meyer, N., Harvey, A. G., Lockley, S. W., & Dijk, D.-J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00877-7 · Cited by 346
Best practice in the management of behavioural and psychological symptoms of dementia
Tible, O. P., Riese, F., Savaskan, E., & von Gunten, A. (2017) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617712979 · Cited by 302
Management of Behavioral and Psychological Symptoms of Dementia
Bessey, L. J., & Walaszek, A. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1049-5 · Cited by 288
Modifiable Risk Factors for Alzheimer’s Disease
Edwards III, G. A., Gamez, N., Escobedo Jr., G., Calderon, O., & Moreno-Gonzalez, I. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00146 · Cited by 253
Circadian rhythms in neurodegenerative disorders
Nassan, M., & Videnovic, A. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00577-7 · Cited by 253
Blackman, J., Swirski, M., Clynes, J., Harding, S., Leng, Y., & Coulthard, E. (2021) · Journal of Sleep Research · doi:10.1111/jsr.13229 · Cited by 141
Pharmacotherapies for sleep disturbances in dementia
McCleery, J., & Sharpley, A. L. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009178.pub4 · Cited by 128
Self-citationWebster, L., Costafreda Gonzalez, S., Stringer, A., Lineham, A., Budgett, J., Kyle, S., Barber, J., & Livingston, G. (2020) · Sleep · doi:10.1093/sleep/zsz251 · Cited by 77
Richardson, K., Loke, Y. K., Fox, C., Maidment, I., Howard, R., Steel, N., Arthur, A., Boyd, P. J., Aldus, C., Ballard, C., et al. (2020) · BMC Medicine · doi:10.1186/s12916-020-01821-5 · Cited by 73
A 2025 update on treatment strategies for the Alzheimer’s disease spectrum
Wu, C.-K., & Fuh, J.-L. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001252 · Cited by 77
Central and peripheral circadian clocks and their role in Alzheimer's disease
Chauhan, R., Chen, K.-F., Kent, B. A., & Crowther, D. C. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.030627 · Cited by 58
Non-pharmacological interventions for sleep disturbances in people with dementia
Wilfling, D., Calo, S., Dichter, M. N., Meyer, G., Möhler, R., & Köpke, S. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011881.pub2 · Cited by 59
Bronskill, S. E., Campitelli, M. A., Iaboni, A., Herrmann, N., Guan, J., Maclagan, L. C., Watt, J., Rochon, P. A., Morris, A. M., Jeffs, L., et al. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15519 · Cited by 54
Teixeira, A. L., Rocha, N. P., & Gatchel, J. (2023) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0043-1777774 · Cited by 33
Wong, A. T. Y., Reeves, G. K., & Floud, S. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13009 · Cited by 28
Metadata
- Authors
- McCleery, J., Cohen, D. A., & Sharpley, A. L.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-11-16
- Volume
- 11
- Pages
- CD009178-CD009178
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2552970977
- Cited by
- 174
- References
- 9
- FWCI
- 19.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.